open access

Vol 48, No 4 (2017)
Prace oryginalne / Original research articles
Published online: 2017-10-01
Submitted: 2017-02-27
Get Citation

Genomic landscape of human erythroleukemia K562 cell line, as determined by next-generation sequencing and cytogenetics

Małgorzata Kurkowiak1, Monika Pępek12, Marcin M. Machnicki12, Iwona Solarska3, Katarzyna Borg3, Małgorzata Rydzanicz4, Piotr Stawiński45, Rafał Płoski4, Tomasz Stokłosa1
DOI: 10.1016/j.achaem.2017.06.002
·
Acta Haematol Pol 2017;48(4):343-349.
Affiliations
  1. Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Poland
  2. Postgraduate School of Molecular Medicine, Warsaw, Poland
  3. Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
  4. Department of Medical Genetics, Medical University of Warsaw, Poland
  5. Department of Genetics, Institute of Physiology and Pathology of Hearing, Kajetany/Warsaw, Poland

open access

Vol 48, No 4 (2017)
Prace oryginalne / Original research articles
Published online: 2017-10-01
Submitted: 2017-02-27

Abstract

We have performed detailed analysis of the genomic landscape of commercially available K562 cells, employing targeted enrichment of nearly 1300 cancer-related genes followed by next-generation sequencing (NGS) and also classical cytogenetics. Deep sequencing revealed 88 variants of potentially biological significance. Among them we have detected alterations in genes already known to be mutated in K562, such as TP53 but also in several other genes, which are implicated in tumorigenesis and drug resistance, such as MLH1, ASXL1 and BRCA1 as the most prominent examples. Fluorescence in situ hybridization (FISH) of interphases of K562 cells revealed multiplication of the BCR and ABL1 gene copies, as well as the amplification of the BCR-ABL1 fusion gene. Our results may help to better understand genomic instability of the blastic phase of CML represented by the K562 cell line and can help researchers who want to employ this cell line in various experimental settings.

Abstract

We have performed detailed analysis of the genomic landscape of commercially available K562 cells, employing targeted enrichment of nearly 1300 cancer-related genes followed by next-generation sequencing (NGS) and also classical cytogenetics. Deep sequencing revealed 88 variants of potentially biological significance. Among them we have detected alterations in genes already known to be mutated in K562, such as TP53 but also in several other genes, which are implicated in tumorigenesis and drug resistance, such as MLH1, ASXL1 and BRCA1 as the most prominent examples. Fluorescence in situ hybridization (FISH) of interphases of K562 cells revealed multiplication of the BCR and ABL1 gene copies, as well as the amplification of the BCR-ABL1 fusion gene. Our results may help to better understand genomic instability of the blastic phase of CML represented by the K562 cell line and can help researchers who want to employ this cell line in various experimental settings.

Get Citation

Keywords

Chronic myeloid leukemia; K562; Human erythroleukemia; Next-generation sequencing; Genomic instability

About this article
Title

Genomic landscape of human erythroleukemia K562 cell line, as determined by next-generation sequencing and cytogenetics

Journal

Acta Haematologica Polonica

Issue

Vol 48, No 4 (2017)

Pages

343-349

Published online

2017-10-01

DOI

10.1016/j.achaem.2017.06.002

Bibliographic record

Acta Haematol Pol 2017;48(4):343-349.

Keywords

Chronic myeloid leukemia
K562
Human erythroleukemia
Next-generation sequencing
Genomic instability

Authors

Małgorzata Kurkowiak
Monika Pępek
Marcin M. Machnicki
Iwona Solarska
Katarzyna Borg
Małgorzata Rydzanicz
Piotr Stawiński
Rafał Płoski
Tomasz Stokłosa

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl